Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, Met Primary Efficacy Endpoint in Phase IIB Keynote-942 Trial

Moderna, Inc. and Merck announced that the Phase IIb KEYNOTE-942 trial of mRNA-4157/V940, in combination with KEYTRUDA®, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival of patients with stage III/IV melanoma following complete resection.